论文部分内容阅读
目的:分析核酸检测(NAT)献血者乙型肝炎病毒(HBV)结果,探讨血站全面开展NAT的必要性。方法:对我站酶免检测无反应性标本,采用PCR-荧光法进行NAT检测,NAT有反应性标本做HBV DNA定量和乙肝“两对半”检测。结果:NAT 31 443份标本,有反应49例(0.16%),其中,HBV DNA定量检测有反应性标本30例,“两对半”定性实验结果为22例HBsAg有反应性,14例HBsAg为临界值的标本,且其中32例合并HBeAb、HBcAb有反应性;13例HBsAb、HBeAb或HBcAb有反应性。结论:NAT能够在一定程度上弥补ELISA方法的局限性,有效缩短窗口期,防止亚型变异或者隐匿性肝炎漏检的风险,有必要在血站全面开展。
Objective: To analyze the results of Hepatitis B virus (HBV) in blood donors by nucleic acid testing (NAT), and to explore the necessity of carrying out NAT in blood stations. Methods: The enzyme immunoassay was used to detect the non-responsive samples. The PCR assay was used to detect the NAT, and the NAT-positive samples were used to detect HBV DNA and hepatitis B virus. RESULTS: There were 49 (0.16%) reactions in 443 specimens of NAT 31, of which 30 were reactive with HBV DNA and 22 were reactive with 22 pairs of HBsAg in 14 pairs of HBsAg was the critical value of the specimens, and 32 cases with HBeAb, HBcAb reactivity; 13 cases of HBsAb, HBeAb or HBcAb reactivity. Conclusion: NAT can make up for the limitation of ELISA method to a certain extent, effectively shorten the window period, prevent the subtype mutation or the risk of occult hepatitis misdetection.